MLXIPL and fatty liver disease: By lowering ChREBP activity and DNL, PF-06835919 inhibited ketohexokinase and prevented fructose-induced hepatic steatosis and hyperinsulinemia in preclinical studies using primary rat hepatocytes and a high fructose diet (79).